Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

North Central Cancer Treatment Group — finding ways to make treatment easier

28.02.2006


Mayo Clinic researchers working in concert with other North Central Cancer Treatment Group (NCCTG) investigators have found that administering epoetin alfa for anemia once every three weeks to patients with anemia and cancer, instead of the traditional weekly epoetin treatments, maintains similar levels of red blood cells. Results of the study are available online in the Journal of Clinical Oncology.



Anemia is a common complication of cancer and can significantly impair a patient’s quality of life, causing tiredness, shortness of breath, dizziness and other problems. Epoetin alfa stimulates bone marrow production of blood cells, thereby reducing anemia. "We are constantly looking for ways to make treatments easier for patients," says David Steensma, M.D., Mayo Clinic oncologist and lead author of the study. "Sometimes this means finding ways to treat side effects. In this case we studied how to treat a side effect without sacrificing as much of the patient’s time and money."

Dr. Steensma and his team studied 360 patients who were randomly assigned to receive either the standard protocol of 40,000 units (40K) of epoetin alfa once a week for 21 weeks, or 40K units of epoetin alfa once a week for three weeks followed by 120,000 units (120K) of epoetin alfa once every three weeks for the remaining 18 weeks. The investigators found no statistical difference in the proportion of patients requiring transfusions due to low hemoglobin between the groups. Side effects, including thromboembolism (blood clot in a blood vessel) and overall survival also were similar. Hemoglobin levels were slightly greater throughout the study for the patients enrolled in the 40K group, but those receiving 120K every three weeks still maintained a level that did not require transfusions. At the end of the study, patients in each group reported a similar quality of life.


While they find the results of this study promising, Dr. Steensma and his team say that a larger study must be done to more definitively show equivalence between the two therapies. Although this reduced frequency dosing schedule would be more convenient for patients, the researchers say that clinicians will have to decide whether the potentially lower hemoglobin levels are an acceptable trade-off.

John Murphy | EurekAlert!
Further information:
http://www.mayo.edu
http://ncctg.mayo.edu
http://cancercenter.mayo.edu

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

Im Focus: Quantum-physical Model System

Computer-assisted methods aid Heidelberg physicists in reproducing experiment with ultracold atoms

Two researchers at Heidelberg University have developed a model system that enables a better understanding of the processes in a quantum-physical experiment...

Im Focus: Glacier bacteria’s contribution to carbon cycling

Glaciers might seem rather inhospitable environments. However, they are home to a diverse and vibrant microbial community. It’s becoming increasingly clear that they play a bigger role in the carbon cycle than previously thought.

A new study, now published in the journal Nature Geoscience, shows how microbial communities in melting glaciers contribute to the Earth’s carbon cycle, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Fraunhofer HHI with latest VR technologies at NAB in Las Vegas

24.04.2017 | Trade Fair News

New quantum liquid crystals may play role in future of computers

21.04.2017 | Physics and Astronomy

A promising target for kidney fibrosis

21.04.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>